Concord Biotech Limited (NSE:CONCORDBIO)

Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 158.24 billion. The enterprise value is 155.09 billion.

Market Cap	158.24B
Enterprise Value	155.09B

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	Sep 3, 2025

Share Statistics

Concord Biotech has 104.62 million shares outstanding. The number of shares has increased by 0.05% in one year.

Current Share Class	104.62M
Shares Outstanding	104.62M
Shares Change (YoY)	+0.05%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	61.13%
Owned by Institutions (%)	14.01%
Float	26.35M

Valuation Ratios

The trailing PE ratio is 44.45 and the forward PE ratio is 35.87. Concord Biotech's PEG ratio is 1.82.

PE Ratio	44.45
Forward PE	35.87
PS Ratio	13.32
PB Ratio	8.73
P/TBV Ratio	8.73
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.82

Enterprise Valuation

EV / Earnings	43.55
EV / Sales	13.05
EV / EBITDA	32.22
EV / EBIT	36.38
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	n/a
Interest Coverage	1,231.57

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	15.94%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	7.56M
Profits Per Employee	2.27M
Employee Count	1,571
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Concord Biotech has paid 1.18 billion in taxes.

Income Tax	1.18B
Effective Tax Rate	24.83%

Stock Price Statistics

The stock price has decreased by -19.60% in the last 52 weeks. The beta is 0.75, so Concord Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-19.60%
50-Day Moving Average	1,624.87
200-Day Moving Average	1,763.50
Relative Strength Index (RSI)	35.12
Average Volume (20 Days)	115,324

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 11.88 billion and earned 3.56 billion in profits. Earnings per share was 34.03.

Revenue	11.88B
Gross Profit	7.71B
Operating Income	4.27B
Pretax Income	4.74B
Net Income	3.56B
EBITDA	4.82B
EBIT	4.27B
Earnings Per Share (EPS)	34.03

Balance Sheet

The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion or 30.09 per share.

Cash & Cash Equivalents	3.18B
Total Debt	29.69M
Net Cash	3.15B
Net Cash Per Share	30.09
Equity (Book Value)	18.13B
Book Value Per Share	173.28
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 64.92%, with operating and profit margins of 35.97% and 29.97%.

Gross Margin	64.92%
Operating Margin	35.97%
Pretax Margin	39.87%
Profit Margin	29.97%
EBITDA Margin	40.60%
EBIT Margin	35.97%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 10.70, which amounts to a dividend yield of 0.71%.

Dividend Per Share	10.70
Dividend Yield	0.71%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-0.05%
Shareholder Yield	0.66%
Earnings Yield	2.25%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1